Recruiting

Clareon TruPlus vs. Clareon Monofocal

Sponsor:

Berkeley Eye Center

Code:

NCT07693205

Conditions

Cataract

Eligibility Criteria

Sex: All

Age: 22+

Healthy Volunteers: Not accepted

Interventions

Clareon TruPlus

Clareon monofocal

Study Details

Brief summary:

This investigator-initiated trial is a prospective, randomized, parallel-group, bilateral implantation study comparing Clareon TruPlus versus Clareon monofocal intraocular lenses (IOLs). Spherical and toric models are permitted in both arms based on standardized preoperative planning and clinical indication. Subjects and postoperative examiners/technicians will be masked to IOL assignment; surgeons will not be masked. The overall structure is modeled after randomized bilateral implantation cataract study designs with a Month 3 primary endpoint visit.

Conditions

Cataract

Study ID

NCT07693205

Start date

Jun 12, 2026

Status verified date

Jul, 2026

Completion date

Jul, 2027

Anticipated

Primary completion date

Jul, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 22+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Adult cataract patients aged ≥22 years scheduled for cataract surgery in both eyes due to visually significant cataracts.
2. Ability to understand and sign an IRB/ethics committee-approved informed consent form.
3. Willingness and ability to attend all scheduled study visits as required by the protocol and complete all study testing procedures.
4. Postoperative potential visual acuity of 20/25 or better in each eye, as determined by the investigator.
5. Preoperative corneal astigmatism that can be corrected with a T3-T5 toric IOL, or with a spherical IOL plus LRIs/Aks, with either resulting in a predicted postoperative astigmatism <0.50 D.
6. IOL power and, if toric, cylinder availability within labeled ranges for the assigned IOL family.
7. Ability to understand and complete study questionnaires.

Exclusion Criteria:

1. Women who are pregnant, planning to become pregnant during the study period, or breastfeeding (by verbal confirmation).
2. Ocular conditions that could confound study results, including moderate-to-severe corneal pathology, irregular astigmatism, moderate-to-severe dry eye/ocular surface disease not optimized, preexisting retinal degenerative disease (e.g., age-related macular degeneration), diabetic retinopathy, or other clinically significant retinal pathology.
3. Any form of confirmed glaucomatous optic neuropathy or other optic nerve disease expected to affect visual function outcomes.
4. History of amblyopia, monofixation syndrome, or other binocular vision disorder with poor stereopsis that could confound binocular testing.
5. Prior ocular surgery (including corneal refractive surgery) in either eye.
6. Zonular laxity/dehiscence, pseudoexfoliation with clinically significant zonulopathy, nystagmus, or strabismus that could compromise uncomplicated surgery or reliable visual testing.
7. Participation in another clinical study (interventional) that could interfere with study results.
8. Planned monovision/mini-monovision or desire for monovision targeting.
9. Systemic conditions that may affect healing or visual outcomes (e.g., uncontrolled diabetes mellitus, certain autoimmune disorders) per investigator judgment.
10. Psychiatric or cognitive disorders that may impair the ability to comply with study procedures or provide reliable self-assessments.
11. Any active ocular infection or inflammation.

Study Design

Enrollment

180 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: Clareon TruPlus

active comparator: Clareon monofocal

Interventions

Clareon TruPlus

Bilateral implantation with Clareon TruPlus

Clareon monofocal

Bilateral implantation with Clareon monofocal

Primary outcome measure

  • Binocular photopic corrected distance visual acuity (CDVA) at 4 m [ Time Frame: 3 months postoperatively ]

Central Contacts and Locations

Central contacts

Locations

Berkeley Eye Center - Sugar Land

Recruiting

Sugar Land, Texas, United States, 77478

Contacts

Tetiana Clinical Research Coordinator

713-526-1600tetiana.huff@berkeleyeye.com

More Information

Sponsor

Berkeley Eye Center

Last update posted

Jul 21, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Berkeley Eye Center on 2026-07-21.